Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan

NCT03649152 is registered in ClinicalTrials.gov with Dimerix Bioscience Pty Ltd as lead sponsor.

NCT NCT03649152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03649152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan
Lead sponsor
Dimerix Bioscience Pty Ltd
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2018
Completion date
July 13, 2020
Enrollment
8 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis